In an earlier study, we have observed an increase of alpha-tocopherol in breast cancer patients treated with third-generation aromatase inhibitors that was related to tamoxifen withdrawal. We report here the results of measurement of alpha-tocopherol in erythrocytes and alpha-tocopherol/cholesterol ratios in patients treated with letrozol. Alpha-tocopherol in lipoprotein fractions and erythrocytes was determined by high-performance liquid chromatography in 124 post-menopausal women with breast cancer treated with letrozol immediately before the start of treatment as well as 2 and 4 mo later. After a transient decrease after 2 mo of letrozol therapy, erythrocyte alpha-tocopherol concentrations returned to pre-treatment levels 4 mo after the start of treatment. Apart from lower cholesterol in patients pre-treated with tamoxifen, no significant differences were observed at baseline between patients previously treated with tamoxifen and patients who had no prior tamoxifen in any of the other parameters investigated, but the transient decrease of erythrocyte alpha-tocopherol was observed only in patients previously treated with tamoxifen. Alpha-tocopherol content of lipoprotein fractions was significantly increased 4 mo after the start of therapy, but this increase was evident mostly in patients not treated earlier with tamoxifen. In conclusion, only minor changes of alpha-tocopherol, including a transient decrease of alpha-tocopherol in erythrocyte membranes, and an increase of alphatocopherol in lipoprotein fractions were observed during the first 4 mo of letrozol therapy.
Third generation aromatase inhibitors (anastrozol, letrozol and exemestane) represent an effective therapy in patients with estrogen and/or progesterone receptorpositive breast carcinoma. The activity of aromatase inhibitors was first demonstrated in patients with advanced disease ( 1-3 ), but subsequent prospective clinical trials have demonstrated an incremental benefit of therapy with third generation aromatase inhibitors in patients with early breast carcinoma when used subsequently to or in place of tamoxifen ( 4 , 5 ) . Currently, the majority of patients with early breast cancer are cured. Comorbid conditions are of great importance in patients with early breast cancer and, in a significant proportion of the patients, comorbid disorders rather than breast cancer are the ultimate cause of death ( 6 ) . Atherosclerosis with its complications is by far the most important cause of morbidity and mortality due to comorbid conditions in patients with breast cancer. The pathogenesis of atherosclerosis is complex, and disorders of antioxidant balance play an important role ( 7 ) .
Vitamin E is the major circulating liposoluble antioxidant. The term vitamin E encompasses several naturally occurring tocopherols and tocotrienols, but alphatocopherol is responsible for most of vitamin E activity in animal tissues ( 8 ) . Disorders of antioxidant balance involving vitamin E may be involved in the toxicity associated with radiotherapy ( 9 , 10 ), or chemotherapy ( 11 ) , and, in earlier studies, a decrease in serum alphatocopherol has been observed during systemic chemotherapy (12) (13) (14) (15) .
Serum or plasma concentrations of alpha-tocopherol are decreased in cancer patients. Erythrocyte alphatocopherol levels may be a more reliable indicator of vitamin E status than serum or plasma concentrations ( 16 ) . For example, in an earlier report, erythrocyte, but not plasma concentrations of alpha-tocopherol were associated with carotid-media thickening in subjects at risk for atherosclerosis ( 17 ) .
In a previous study, an increase of alpha-tocopherol was observed in breast cancer patients after therapy E-mail: bohuslav.melichar@fnol.cz with third generation aromatase inhibitors that was associated with increased serum total very low density lipoprotein (VLDL) and low-density lipoprotein (LDL) cholesterol concentrations ( 18 ) . The increase of alphatocopherol and cholesterol was restricted to patients pre-treated with tamoxifen, and a statistically significant decrease of alpha-tocopherol/cholesterol ratio was evident after tamoxifen withdrawal. The aim of the present study was to analyze erythrocyte alpha-tocopherol and alpha-tocopherol/cholesterol ratios in lipoprotein fractions in a part of the same patient cohort treated with letrozol.
PATIENTS AND METHODS
One hundred and twenty-four post-menopausal women, aged (mean Ϯ SD) 63 Ϯ 11 (range 36-86) y, with histologically verified breast carcinoma were included in the present study. The patients were evaluated immediately before, and 2 mo and 4 mo after the start of therapy with letrozol (2.5 mg/d). All patients were treated with letrozol as part of their standard care in the adjuvant, neoadjuvant or curative setting. Ninety-two patients, 57 patients who had prior systemic chemotherapy and 35 patients who had no prior systemic treatment, were treated with letrozol as the first hormonal agent and 32 patients had letrozol after prior hormonal therapy with tamoxifen. The study was approved by the institutional ethical committee, and the patients signed informed consent forms.
Blood samples were drawn from the peripheral vein after an overnight fast. The samples were transferred immediately to the laboratory and centrifuged (2,000 ϫ g , 10 min, 4˚C) and the serum was separated and analyzed immediately or frozen at Ϫ 20˚C until analysis. Serum lipoproteins were immediately separated into VLDL, LDL and high-density lipoprotein (HDL) fractions using gradient ultracentrifugation in sodium chloride solutions (OPTIMA MAX-XP ultracentrifuge, Beckman Coulter, Fullerton, CA, USA). Cholesterol in serum and lipoprotein fractions was determined on a MODULAR analyzer (Hoffmann-La Roche, Basel, Switzerland) using commercially available kits.
For the separation of erythrocytes, samples were centrifuged immediately (2,000 ϫ g , 10 min, 4˚C). After the separation of the plasma, the erythrocytes were washed three times with 0.9% sodium chloride solution containing 0.01% butylated hydroxyl-toluene and subsequently diluted 1 : 1 (v : v) with the same solution ( 19 ) . The samples were then stored in liquid nitrogen at Ϫ 170˚C until analysis. Subsequently, in the liquid-liquid extraction procedure, 2,500 L of n -hexane was added to 500 L of erythrocytes mixture in a glass stoppered test tube. After 2 min this mixture was deproteinized by addition of cool ethanol denatured with 5% methanol (500 L, 5 min) containing an internal standard of alpha-tocopherol acetate (final concentration 20 mol/L), and then extracted for 5 min by vortex mixing. After centrifugation (1,900 ϫ g , 10 min, 0˚C) an aliquot (2,000 L) of the clean extract was separated and evaporated in a concentrator (AD5301, Eppendorf, Hamburg, Germany) at 45˚C. The residue was dissolved in 400 L of methanol and analysed by reversed-phase HPLC using internal standard calibration ( 19 ) .
Serum and lipoprotein alpha-tocopherol was determined by high performance liquid chromatography as described ( 20 ) . In the liquid-liquid extraction procedure, 500 L of sample consisting of either serum or lipoprotein fraction was de-proteinized by cool ethanol denatured with 5% methanol (500 L, 5 min, 4˚C) for the determination of alpha-tocopherol. Subsequently, 2,500 L of n -hexane was added to this mixture and extracted for 5 min with a vortex apparatus. After centrifugation (2,000 ϫ g , 10 min, 0˚C), the aliquot (2,000 L) of the clean extract was separated and evaporated in a AD5301 concentrator (45˚C). The residue was dissolved in 400 L methanol and analyzed by reversed-phase high performance liquid chromatography using the external standard calibration. The analyses were performed using the Perkin Elmer high performance liquid chromatography set (Norwalk, CT, USA) comprising a LC 200 pump, a LC 200 autosampler, LC Column Oven 101 thermostat and LC 235C Diode Array Detector attached to the Perkin Elmer Turbochrom Chromatography Workstation version 4.1. Separation of alpha-tocopherol was performed using the Chromolith Performance RP-18e, 100 ϫ 4.6 mm monolithic columns (Merck, Darmstadt, Germany). As the mobile phase 100% methanol was used at the flow rate of 2.5 mL·min Ϫ 1 and column pressure of 3.3 MPa. The block heater LC Oven 101 (Perkin Elmer) was utilized to keep the analytical column temperature at 25˚C. The injection volume was 50 L. The detection of alphatocopherol was carried out at 295 nm. Total time of analysis was 2.5 min.
The parameters before and during the treatment were compared by the Wilcoxon signed rank test. Differences between different groups were analyzed by the Mann-Whitney U test. The decision on statistical significance was based on the p ϭ 0.05 level. The analyses were performed using NCSS software (Number Cruncher Statistical Systems, Kaysville, Utah, USA).
RESULTS
The changes of alpha-tocopherol in erythrocytes and lipoprotein fractions are summarized in Table 1 . After a transient decrease after 2 mo of letrozol therapy, erythrocyte alpha-tocopherol concentrations returned to pre-treatment levels 4 mo after the start of treatment. Apart from lower cholesterol in patients pre-treated with tamoxifen, no significant differences were evident between patients previously treated with tamoxifen and patients who had no prior tamoxifen in baseline values of the other parameters investigated (Tables 2 and 3 ). The transient decrease of erythrocyte alpha-tocopherol was observed only in patients previously treated with tamoxifen (Table 2) . Alpha-tocopherol content of lipoprotein factions was significantly increased 4 mo after the start of therapy, but this increase was evident mostly in patients not treated earlier with tamoxifen (Table 3) .
DISCUSSION
In this report, we present the results of an analysis of erythrocyte alpha-tocopherol and lipoprotein alphatocopherol/cholesterol ratios in patients with breast carcinoma during the first 4 mo of therapy with letrozol. In an earlier investigation that included the present cohort of patients, we observed an increase of cholesterol and alpha-tocopherol after tamoxifen withdrawal Values represent the mean Ϯ SD of the respective parameters. Values represent the meanϮSD of the respective parameters.
(18). Here we present additional investigations in a more homogeneous subgroup of patients treated with letrozol that were not published in the initial report. Only relatively minor changes were observed in the parameters investigated. The erythrocyte membrane alpha-tocopherol concentrations were decreased after 2 mo of therapy, but returned to pre-treatment levels at 4 mo. This decrease was observed only in patients pretreated with tamoxifen. An increase of alpha-tocopherol/cholesterol ratios in VLDL, LDL and HDL was evident after 4 mo of therapy, but this increase was mostly restricted to patients not pre-treated with tamoxifen. Serum alpha-tocopherol reflects oxidative stress caused by the tumor activity or cancer treatment, e.g. chemotherapy. It has been demonstrated in earlier studies that alpha-tocopherol decreased in cancer patients, and further decrease may be observed after administration of cytotoxic agents (12, 13, 15) . The increase of serum alpha-tocopherol/cholesterol ratio in lipoprotein fractions may be explained by gradual recovery from earlier chemotherapy that was administered in the majority of patients not pre-treated with tamoxifen. An increase of serum alpha-tocopherol has also been described after effective antitumor therapy (21) , and, in the present cohort, the increase of alpha-tocopherol/cholesterol ratio in lipoprotein fractions could also be the result of tumor control by letrozol administered in the adjuvant or curative setting. In earlier studies, tamoxifen withdrawal was associated with alterations of lipid metabolism resulting in a marked increase in serum cholesterol concentrations (18) . As indicated in Table 2 , a marked increase of serum cholesterol concentrations was observed in patients pre-treated with tamoxifen also in the present cohort. This increase of cholesterol concentrations could have resulted in dilution of alpha-tocopherol in lipoproteins or cell membranes. This dilution may partly explain the decrease of erythrocyte alpha-tocopherol or absence of an increase of alphatocopherol/cholesterol ratio in lipoproteins that were observed in patients pre-treated with tamoxifen despite the increase of alpha-tocopherol concentrations. Currently, the use of aromatase inhibitors is restricted to postmenopausal women, many of them elderly. Postmenopausal status and age are associated with increased risk of atheroslerosis (22) . The present data are of significance as aromatase inhibitors are being used for prolonged periods of time in patients treated with curative intent. Therefore, changes in the parameters that determine the risk of atherosclerosis may be of importance for decisions regarding patient management.
Lipid peroxidation is thought to play a crucial role in the pathogenesis of atherosclerosis. Lipid peroxidation is driven by oxidative stress and inhibited by circulating antioxidants. Alpha-tocopherol is considered the major liposoluble antioxidant in the circulation, and erythrocyte alpha-tocopherol concentrations have been associated with an early indicator of atherosclerosis, carotid intima-media thickening (17) . On the other hand, experimental studies have demonstrated the phenomenon of tocopherol-mediated peroxidation (23) , and, under different circumstances, alpha-tocopherol may behave as a prooxidant or antioxidant. Thus, under certain conditions, alpha-tocopherol in membranes or lipoproteins may actually enhance lipid peroxidation and foster the progression of atherosclerosis (23) . Erythrocyte alpha-tocopherol concentrations at the end of the study period were unchanged. From the point of view of clinical practice, this finding may be reassuring. However, we have to consider the possibility of alphatocopherol redistribution from tissues to the plasma as proposed by Blatt et al. (24) . The absence of change of erythrocyte and lipoprotein alpha-tocopherol could result from a compensatory redistribution of alphatocopherol from tissues to plasma. Further studies are needed to clarify this phenomenon. The observation period of the present study was only 4 mo, and no conclusion can be made regarding the long-term effect of letrozol treatment on alpha-tocopherol concent of erythrocytes and lipoprotein fractions. Thus, at present it may be too early to determine whether the changes of alpha-tocopherol metabolism associated with letrozol therapy have any impact on long-term risk of atherosclerosis.
In conclusion, only minor changes of alpha-tocopherol, including a transient decrease of alpha-tocopherol in erythrocyte membranes and an increase of alphatocopherol in lipoprotein fractions were observed during the first 4 mo of letrozol therapy.
